Top 10 Early Stage Investors: Biotechnology/LifeSciences
| Rank | Investor Name |
|---|---|
| 1 | ORBIMED Healthcare Fund Management |
| 2 | RA Capital Management |
| 3 | ARCH Venture Partners |
| 4 | Eli Lilly and Company |
| 5 | Even One Ventures |
| 6 | Atlas Ventures |
| 7 | BVF Partners |
| 8 | Novo Holdings |
| 9 | versant ventures |
| 10 | Yosemite |
Early stage activity in this category is led by institutional venture franchises and category specialists. Clinical data readouts and large pharma acquisition appetite set the pace of investment across biotech, with capital concentrating in firms that can underwrite science. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.